t224 - rOle e 1 (Olive)
Test details
This test is useful when a pollen allergy to the Oleaceae family is suspected and to identify the specific molecule that has previously caused a positive result in the associated allergen extract test.
Ole e 1 is a protein present in olive pollen and is the most frequent cause of allergies in the population of the Mediterranean region.
The average prevalence of this molecule is up to 80% in patients sensitised to olive pollen.
Cross-reactivity is possible with other pollens such as privet, ash, lilac, plantain, ryegrass and timothy grass.
Symptoms associated with an allergy to this molecule mainly include allergic rhinitis, conjunctivitis, and coughing caused an itchy throat; in some cases, the allergy may also cause skin symptoms and lead to bronchial asthma.
The assessment of sensitisations to Ole e 1 is considered important for selecting patients eligible for allergen-specific immunotherapy (AIT).
Sample type
Serum, EDTA plasma, heparin plasma, citrate plasma
Method
IFA tissue
Preparation
Fasting for at least 8-12 hours before sampling
Storage conditions
Refer to the Health Service Charter to check storage conditions
Shipping
+2/+8°C
References
Hamilton RG. Allergic sensitization is a key risk factor for but not synonymous with allergic disease. J Allergy Clin Immunol. 2014 Aug;134(2):360-1. doi: 10.1016/j.jaci.2014.02.022. Epub 2014 Mar 31. PMID: 24698318.
Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R, Hilger C, et al. EAACI Molecular Allergology User's Guide. Pediatr Allergy Immunol. 2016 May;27 Suppl 23:1-250. doi: 10.1111/pai.12563. PMID: 27288833.
laboratory analysis
Find other tests
Total tau
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
Phosphorylated Tau (pTau181)
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Anti–NMDAR Antibodies
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Discover what’s new
Subscribe to the newsletter
Subscribe to our newsletter to be always updated.